SCAI-001 0.01% eyedrop
DrugBID for 12weeks
Other names: Cyclosporine 0.01%
NCT Number: NCT05733624
This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Phase 2
The Catholic University of korea, Bucheon ST.Mary's Hospital, Bucheon-si, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BID for 12weeks
Other names: Cyclosporine 0.01%
BID for 12weeks
Other names: Cyclosporine 0.02%
BID for 12weeks
Other names: Cyclosporine 0.05%
Time frame: Change from baseline at 12 weeks
Schirmer's test
Time frame: Change from baseline at 4, 8 weeks
Schirmer's test
Time frame: Change from baseline at 4, 8, 12 weeks
Oxford grading
Time frame: Change from baseline at 4, 8, 12 weeks
Oxford grading
Time frame: Change from baseline at 4, 8, 12 weeks
Measured three times and recorded up to 1/100
Time frame: Change from baseline at 4, 8, 12 weeks
written by the subject
Time frame: Change from baseline at 4, 8, 12 weeks
written by the subject
Time frame: 12weeks
sourced by patient diary
SCAI Therapeutics
Industry
A Multicenter, Active Control, Parallel Group, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops in Patients With Dry Eye Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05481450
Dry Eye, Dry Eye Syndromes
Lutz, Florida, United States
View Trial DetailsNCT06483750
Cataract Senile, Dry Eye Disease
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07588074
Conjunctival Diseases, Conjunctivitis
Baton Rouge, Louisiana, United States
View Trial DetailsNCT04730336
Dry Eye, Dry Eye Syndromes
Solihull, United Kingdom
View Trial Details